[1]张盼盼,董琪,华英彬,等.贝伐单抗对人视网膜色素上皮细胞形态、凋亡率及凋亡相关因子表达的影响[J].眼科新进展,2018,38(4):314-318.[doi:10.13389/j.cnki.rao.2018.0074]
　ZHANG Pan-Pan,DONG Qi,HUA Ying-Bin,et al.Effects of bevacizumab on morphology and apoptosis of human retinal pigment epithelial cells as well as the expression of apoptosis-related factors[J].Recent Advances in Ophthalmology,2018,38(4):314-318.[doi:10.13389/j.cnki.rao.2018.0074]
点击复制

贝伐单抗对人视网膜色素上皮细胞形态、凋亡率及凋亡相关因子表达的影响/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
38卷
期数:
2018年4期
页码:
314-318
栏目:
实验研究
出版日期:
2018-04-05

文章信息/Info

Title:
Effects of bevacizumab on morphology and apoptosis of human retinal pigment epithelial cells as well as the expression of apoptosis-related factors
作者:
张盼盼; 董琪; 华英彬; 徐海峰
250022　山东省济南市，济南大学 山东省医学科学院医学与生命科学学院 山东省眼科研究所 青岛眼科医院（张盼盼）；266071　山东省青岛市，山东省眼科研究所 青岛眼科医院（董琪，华英彬，徐海峰）
Author(s):
ZHANG Pan-Pan; DONG Qi; HUA Ying-Bin; XU Hai-Feng
University of Jinan，School of Medicine and Life Science，Shandong Eye Institute，Qingdao Eye Hospital （ZHANG Pan-Pan），Jinan 250022，Shandong Province，China；Qingdao Eye Hospital，Shandong Eye Institute （DONG Qi，HUA Ying-Bin，XU Hai-Feng），Qingdao 266071，Shandong Province，China
关键词:
年龄相关性黄斑变性; 贝伐单抗; 人视网膜色素上皮细胞; 细胞凋亡率; 凋亡因子
Keywords:
age-related macular degeneration; bevacizumab; human retinal pigment epithelial cells; cell apoptosis rate; apoptosis factors
分类号:
R774
DOI:
10.13389/j.cnki.rao.2018.0074
文献标志码:
A
摘要:
目的　探讨贝伐单抗对人视网膜色素上皮细胞形态、凋亡率及凋亡相关因子表达的影响。方法　用含终浓度为0.25 g·L-1贝伐单抗的DMEM/F12培养液培养人视网膜色素上皮细胞（ARPE-19），根据培养时间的不同分为1周加药组、2周加药组，同时设立1周对照组和2周对照组；用光镜观察各组细胞形态；采用流式细胞仪检测各组细胞凋亡情况；用实时荧光定量PCR和Western blot检测凋亡促进基因P53、TP53INP1、Bax以及凋亡抑制基因Bcl-2的mRNA和相应蛋白的表达情况。结果　光镜下观察发现1周对照组和2周对照组的细胞呈典型上皮细胞形态，细胞形态呈铺路石样，单层贴壁样生长。贝伐单抗处理不同时间后，显微镜下观察发现，1周加药组和2周加药组的部分细胞形态略有改变，出现变圆的细胞，胞体拉长，边界欠清。1周对照组、1周加药组、2周对照组、2周加药组的细胞凋亡率分别为（5.57±1.46）%、（6.39±1.25）%、（6.88±1.10）%、（13.34±1.94）%，1周加药组、1周对照组和2周对照组间细胞凋亡率差异均无统计学意义（均为P>0.05）；2周加药组的细胞凋亡率均高于1周对照组、2周对照组和1周加药组，差异均有统计学意义（均为P<0.05）。与1周对照组相比，1周加药组的凋亡促进因子P53、TP53INP1、Bax mRNA的表达均升高，而凋亡抑制因子Bcl-2 mRNA的表达则降低，差异均有统计学意义（均为P<0.05）；2周加药组P53、TP53INP1、Bax mRNA的表达均高于2周对照组和1周加药组，而Bcl-2 mRNA的表达则降低，差异均有统计学意义（均为P<0.05）；1周对照组和2周对照组相比，各因子的表达差异均无统计学意义（均为P>0.05）。各因子蛋白的表达情况与mRNA类似。结论　贝伐单抗能改变ARPE-19细胞的形态，上调ARPE-19细胞的凋亡率和凋亡促进因子的表达，下调凋亡抑制因子的表达，可能是抗VEGF治疗后黄斑部视网膜色素上皮层缺失的原因之一。
Abstract:
Objective　To investigate the effects of bevacizumab on cell morphology，apoptosis rate and apoptosis-related factors in human retinal pigment epitheliumcells.Methods　Human retinal pigment epithelial cells (ARPE-19) were cultured in DMEM/F12 medium containing 0.25 g·L-1 bevacizumab and divided into 1-week dosing group and 2-week dosing group according to the different incubation time，respectively.Meanwhile，the control group was set up.Then，the cell morphology and apoptosis of each group were observed by light microscope and flow cytometry，accordingly.The expression levels of apoptosis-promoting genes P53，TP53INP1，Bax and apoptosis-inducible gene Bcl-2 mRNA and protein were detected by RT-PCR and Western blot，respectively.Results　Light microscopic observation revealed that the cells in the 1-week control group and the 2-week control group showed typical epithelial cell morphology，and were in stone-like，single-layer adherent-like growth.Compared with the control group，part of the cell morphology after bevacizumab treatment changed slightly，and the cells became rounded，the cell body was elongated and the boundary was poor.The apoptotic rates of the 1-week control group，1-week dosing group，2-week control group and 2-week dosing group were (5.57±1.46)%，(6.39±1.25)%，(6.88±1.10)% and (13.34±1.94)%，respectively，and there was no significant difference in the apoptotic rate between 1-week control group，1-week dosing group and 2-week control group (both P>0.05)，but the apoptotic rate of the 2-week dosing group was significantly higher than that of the 2-week control group，the 1-week dosing group and 1-week control group，and the differences were statistically significant (all P<0.01).RT-PCR and Western blot results showed that compared with the 1-week control group，the expression of P53，TP53INP1 and Bax mRNA was up-regulated in 1-week dosing group，but the expression of Bcl-2 mRNA was down-regulated，and the differences were statistically significant (all P<0.05).The expression levels of P53，TP53INP1 and Bax mRNA in 2-week dosing group were higher than those in 2-week control group and 1-week dosing group，while Bcl-2 mRNA expression was down-regulated，and the differences were statistically significant (all P<0.05).There was no significant difference in the expression of the above factors in 1-week control group and 2-week control group(all P>0.05).The protein expressions of above factors were similar to their mRNA expression.Conclusion　Bevacizumab can alter the morphology of ARPE-19 cells，increase the apoptotic rate and up-regulate the expression of apoptosis-promoting factors，but down-regulate the expression of apoptosis-suppression factors in ARPE-19 cells，which may be the reason for the loss of RPE layer in the macula after anti-VEGF therapy.

参考文献/References:

［1］　ROSENFELD PJ，BROWN DM，HEIER JS，BOYER DS，KAISER PK，CHUNG CY，et al.Ranibizumab for neovascular age-related macular degeneration［J］.N Engl J Med，2006，355（14）：1419-1431.
［2］　BROWN DM，KAISER PK，MICHELS M，SOUBRANE G，HEIER JS，KIM RY，et al.Ranibizumab versus verteporfin for neovascular age related macular degeneration［J］.N Engl J Med，2006，355（14）：1432-1444.
［3］　MARTIN DF，MAGUIRE MG，FINE SL，YING GS，JAFFE GJ，GRUNWALD JE，et al.Ranibizumab and Bevacizumab for treatment of neovascular age-related macular degeneration：two-year results［J］.Ophthalmology，2012，119 （7）：1388-1398.
［4］　GRUNWALD JE，DANIEL E，HUANG J，YING GS，MAGUIRE MG，TOTH CA，et al.Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials［J］.Ophthalmology，2014，121（1）：150-161.
［5］　GRUNWALD JE，PISTILLI M，YING GS，MAGUIRE MG，DANIEL E，MARTIN DF，et al.Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials［J］.Ophthalmology，2015，122（4）：809-816.
［6］　CHAKRAVARTHY U，HARDING SP，ROGERS CA，DOWNES SM，LOTERY AJ，CULLIFORD LA，et al.Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation：2-year findings of the IVAN randomised controlled trial［J］.Lancet，2013，382（9900）：1258-1267.
［7］　LOIS N，MCBAIN V，ABDELKADER E，SCOTT N，KUMARI R.Retinal pigment epithelial atrophy in patients with exudative agerelated macular degeneration under going anti-vascular endothelial growth factor therapy［J］.Retina，2013，33（1）：13-22.
［8］　AREND N，WERTHEIMER C，LAUBICHLER P，WOLF A，KAMPIK A，KERNT M.Idebenone prevents oxidative stress，cell death and senescence of retinal pigment epithelium cells by stabilizing Bax/Bcl-2 ratio［J］.Ophthalmologica，2015，234（2）：73-82.
［9］　YING GS，KIM BJ，MAGUIRE MG，HUANG J，DANIEL E，JAFFE GJ，et al.Sustained visual acuity loss in the comparison of age-related macular degeneration treatments trials［J］.JAMA Ophthalmol，2014，132（8）：915-921.
［10］　LI X，XU G，WANG Y，XU X，LIU X，TANG S，et al.Safety and efficacy of conbercept in neovascular age-related macular degeneration［J］.Ophthalmology，2014，121（9）：1740-1747.
［11］　DANIEL E，SHAFFER J，YING GS，GRUNWALD JE，MARTIN DF，JAFFE GJ，et al.Outcomes in eyes with retinal angiomatous proliferation in the comparison of age-related macular degeneration treatments trials［J］.Ophthalmology，2016，123（3）：609-616.
［12］　MUNK MR，CEKLIC L，EBNETER A，HUF W，WOLF S，ZINKERNAGEL MS，et al.Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration［J］.Acta Ophthalmol，2016，94（8）：e757-e764.
［13］　HWANG JC，DEL PRIORE LV，FREUND KB，CHANG S，IRANMANESH R.Development of subretinal fibrosis after anti-vegf treatment in neovascular age-related macular degeneration［J］.Ophthalmic Surg Lasers Imaging，2011，42（1）：6-11.
［14］　DUNAIEF JL，DENTCHEV T，YING GS，MILAM AH.The role of apoptosis in age-related macular degeneration［J］.Arch Ophthalmol，2002，120（11）：1435-1442.
［15］　SHARMA G，RANA NK，SINGH P，DUBEY P，PANDEY DS，KOCH B.p53 dependent apoptosis and cell cycle delay induced by heteroleptic complexes in human cervical cancer cells［J］.Biomed Pharmacother，2017，88：218-231.
［16］　SETOGUCHI K，TESLAA T，KOEHLER CM，TEITELL MA.P53 regulates rapid apoptosis in human pluripotent stem cells［J］.J Mol Biol，2016，428（7）：1465-1475.
［17］　RYU HW，SHIN DH，LEE DH，CHOI J，HAN G，LEE KY，et al.HDAC6 deacetylates p53 at lysines 381/382 and differentially coordinates p53-induced apoptosis［J］.Cancer Lett，2017，391：162-171.
［18］　AI G，DACHINENI R，KUMAR DR，MARIMUTHU S，ALFONSO LF，BHAT GJ，et al.Aspirin acetylates wild type and mutant p53 in colon cancer cells：identification of aspirin acetylated sites on recombinant p53［J］.Tumor Biol，2016，37（5）：6007-6016.
［19］　SEILLIER M，PEUGET S，GAYET O，GAUTHIER C，N’GUESSAN P，MONTE M，et al.TP53INP1，a tumor suppressor，interacts with LC3 and ATG8-family proteins through the LC3-interacting region （LIR） and promotes autophagy-dependent cell death［J］.Cell Death Differ，2012，19（9）：1525-1535.
［20］　OKAMURA S，ARAKAWA H，TANAKA T，NAKANISHI H，NG CC，TAYA Y，et al.p53 DINP1，a p53-inducible gene，regulates p53-dependent apoptosis［J］.Mol Cell，2001，8（1）：85-94.
［21］　WEI Q，LI YX，LIU M，LI X，TANG H.MiR-17-5p Targets TP53INP1 and regulates cell proliferation and apoptosis of cervical cancer cells［J］.Iubmb Life，2012，64（8）：697-704.
［22］　TOMASINI R，SAMIR AA，CARRIER A，ISNARDON D，CECCHINELLI B，SODDU S，et al.TP53INP1s and homeodomain- interacting protein kinase-2 （HIPK2） are partners in regulating p53 activity［J］.J Biol Chem，2003，278（39）：37722-37729.
［23］　LEU J，DUMONT P，HAFEY M，MURPHY ME，GEORGE DL.Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex［J］.Nat Cell Biol，2004，6（5）：443-450
［24］　MIHARA M，ERSTER S，ZAIKA A，PETRENKO O，CHITTENDEN T，PANCOSKA P，et al.P53 has a direct apoptogenic role at the mitochondria［J］.Mol Cell，2003，11（3）：577-590.
［25］　VOUSDEN KH，LU X.Live or let die：the cell’s response to p53［J］.Nat Rev Cancer，2002，2（8）：594-604.
［26］　SAVORY J，RAO JK，HUANG Y，LETADA PR，HERMAN MM.Age-related hippocampal changes in Bcl-2：Bax ratio，oxidative stress，redox-active iron and apoptosis associated with aluminum-induced neurodegeneration：increased susceptibility with aging［J］.Neurotoxicology，1999，20（5）：805-817.
［27］　ADAMS JM，CORY S.The Bcl-2 protein family：arbiters of cell survival［J］.Science，1998，281（5381）：1322-1326.

相似文献/References:

[1]范姜砾 王雨生 张鹏.湿性年龄相关性黄斑变性患者血浆中相关抗氧化酶水平测定[J].眼科新进展,2012,32(5):000.
[2]麻南 李丹 高付林 胡莲娜.玻璃体内注射贝伐单抗和贝伐单抗/曲安奈德联合用药治疗糖尿病性黄斑水肿疗效及安全性差异的荟萃分析[J].眼科新进展,2012,32(6):000.
[3]王毅 李罗翔 李娟 曾庆华.ApoE基因缺失小鼠视网膜及Bruch膜组织形态观察[J].眼科新进展,2013,33(1):000.
[4]徐新荣 仲路 黄冰林 魏源华 周欣 王玲 王富强.年龄相关性黄斑变性血浆蛋白质组学初步研究[J].眼科新进展,2013,33(2):000.
[5]党亚龙 陈彬川 穆雅林 赵满丽 朱豫.i-MP对产生2型脉络膜新生血管的年龄相关性黄斑变性患者视力及黄斑厚度的影响[J].眼科新进展,2013,33(2):000.
[6]王毅 李罗翔 李进辉 李娟 曾庆华.血脂异常ApoE基因缺失小鼠视网膜色素上皮细胞胞浆内黑色素和脂褐素的改变[J].眼科新进展,2013,33(7):000.
[7]罗文婷 孙大卫.血管黏附蛋白-1在眼科疾病中的研究进展[J].眼科新进展,2013,33(8):000.
[8]陆秉文 吴星伟.光动力疗法治疗年龄相关性黄斑变性的研究进展[J].眼科新进展,2013,33(4):000.
[9]栾兰 姚勇.湿性年龄相关性黄斑变性的治疗进展[J].眼科新进展,2013,33(4):000.
[10]胡艳红 祁明信 郭娜 陈胜 柯发杰.渗出型年龄相关性黄斑变性患者外周血CCR3的表达[J].眼科新进展,2013,33(11):000.
[11]张照华,杨玲玲,张盼盼,等.贝伐单抗对视网膜色素上皮细胞抗氧化功能的影响[J].眼科新进展,2017,37(4):305.[doi:10.13389/j.cnki.rao.2017.0077]
　ZHANG Zhao-Hua,YANG Ling-Ling,ZHANG Pan-Pan,et al.Effects of bevacizumab on antioxidative function in human retinal pigment epithelial cells[J].Recent Advances in Ophthalmology,2017,37(4):305.[doi:10.13389/j.cnki.rao.2017.0077]

备注/Memo

备注/Memo:
山东省自然科学基金（编号：ZR2014HM029）
更新日期/Last Update: 2018-04-02